Techulon Awarded $1.9M to Defeat “Superbugs”
News May 09, 2013
Techulon, Inc. announced that it has been selected by the Defense Advanced Research Projects Agency (DARPA) for a Phase II contract to advance its therapeutic program for multi-drug resistant bacteria, or ‘superbugs.’ This award drives Techulon’s development of a nanotherapeutic agent that will give the Department of Defense and hospitals the ability to rapidly respond and treat patients with life-threatening multi-drug resistant infections. Techulon successfully completed an early feasibility program of its technology platform in 2012 with DARPA leading up to the current award.
Drug-resistant bacteria are a pervasive and growing problem to both military and civilian healthcare facilities and create over $30b in cost and 100,000 deaths per year. Funding from DARPA will provide resources for Techulon to advance its technology through critical milestones toward human clinical trials.
“We are pleased to extend our work in Rapidly-Adaptable Therapeutics with DARPA. This program will lead to better therapies for wounded soldiers and civilians affected by multi-drug resistant hospital-acquired infections,” commented Dr. Joshua Bryson, CSO at Techulon.
Dr. Brett Malone, Techulon's President commented, “Our partnership with DARPA helps us continue to build value in our clinical initiatives and ultimately have an impact on the healthcare industry with a new generation of therapeutics. Our approach is feasible in many disease areas, including drug-resistant infections, and we are excited to be working with the agency to solve such a devastating problem.”
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE
Chemists Design 'Mini-ecosystems' to Test Drug FunctionNews
Scripps Research scientists have solved a major problem in chemistry and drug development by using droplet-sized 'miniecosystems' to quickly see if a molecule can function as a potential therapeutic.READ MORE
Targeting the Engine Room of the Cancer CellNews
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018